Novel vaccine vectors for HIV.1

Dan H. Barouch, Louis Picker

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The ultimate solution to the global HIV.1 epidemic will probably require the development of a safe and effective vaccine. Multiple vaccine platforms have been evaluated in preclinical and clinical trials, but given the disappointing results of clinical efficacy studies so far, novel vaccine approaches are needed. In this Opinion article, we discuss the scientific basis and clinical potential of novel adenovirus and cytomegalovirus vaccine vectors for HIV.1 as two contrasting but potentially complementary vector approaches. Both of these vector platforms have demonstrated partial protection against stringent simian immunodeficiency virus challenges in rhesus monkeys using different immunological mechanisms.

Original languageEnglish (US)
Pages (from-to)765-771
Number of pages7
JournalNature Reviews Microbiology
Volume12
Issue number11
DOIs
StatePublished - Jan 1 2014

Fingerprint

Vaccines
Cytomegalovirus Vaccines
Adenovirus Vaccines
Simian Immunodeficiency Virus
Macaca mulatta
Clinical Trials
Clinical Studies

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Novel vaccine vectors for HIV.1. / Barouch, Dan H.; Picker, Louis.

In: Nature Reviews Microbiology, Vol. 12, No. 11, 01.01.2014, p. 765-771.

Research output: Contribution to journalArticle

Barouch, Dan H. ; Picker, Louis. / Novel vaccine vectors for HIV.1. In: Nature Reviews Microbiology. 2014 ; Vol. 12, No. 11. pp. 765-771.
@article{5f30e998c35b4f90842dfc7405662506,
title = "Novel vaccine vectors for HIV.1",
abstract = "The ultimate solution to the global HIV.1 epidemic will probably require the development of a safe and effective vaccine. Multiple vaccine platforms have been evaluated in preclinical and clinical trials, but given the disappointing results of clinical efficacy studies so far, novel vaccine approaches are needed. In this Opinion article, we discuss the scientific basis and clinical potential of novel adenovirus and cytomegalovirus vaccine vectors for HIV.1 as two contrasting but potentially complementary vector approaches. Both of these vector platforms have demonstrated partial protection against stringent simian immunodeficiency virus challenges in rhesus monkeys using different immunological mechanisms.",
author = "Barouch, {Dan H.} and Louis Picker",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/nrmicro3360",
language = "English (US)",
volume = "12",
pages = "765--771",
journal = "Nature Reviews Microbiology",
issn = "1740-1526",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Novel vaccine vectors for HIV.1

AU - Barouch, Dan H.

AU - Picker, Louis

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The ultimate solution to the global HIV.1 epidemic will probably require the development of a safe and effective vaccine. Multiple vaccine platforms have been evaluated in preclinical and clinical trials, but given the disappointing results of clinical efficacy studies so far, novel vaccine approaches are needed. In this Opinion article, we discuss the scientific basis and clinical potential of novel adenovirus and cytomegalovirus vaccine vectors for HIV.1 as two contrasting but potentially complementary vector approaches. Both of these vector platforms have demonstrated partial protection against stringent simian immunodeficiency virus challenges in rhesus monkeys using different immunological mechanisms.

AB - The ultimate solution to the global HIV.1 epidemic will probably require the development of a safe and effective vaccine. Multiple vaccine platforms have been evaluated in preclinical and clinical trials, but given the disappointing results of clinical efficacy studies so far, novel vaccine approaches are needed. In this Opinion article, we discuss the scientific basis and clinical potential of novel adenovirus and cytomegalovirus vaccine vectors for HIV.1 as two contrasting but potentially complementary vector approaches. Both of these vector platforms have demonstrated partial protection against stringent simian immunodeficiency virus challenges in rhesus monkeys using different immunological mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=84922480581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922480581&partnerID=8YFLogxK

U2 - 10.1038/nrmicro3360

DO - 10.1038/nrmicro3360

M3 - Article

C2 - 25296195

AN - SCOPUS:84922480581

VL - 12

SP - 765

EP - 771

JO - Nature Reviews Microbiology

JF - Nature Reviews Microbiology

SN - 1740-1526

IS - 11

ER -